RVMD

Revolution Medicines, Inc.

$186.22

+$2.32 (1.26%)Oct 27 close

Healthcare Compare Technicals

1M 3M 6M 1Y 2Y

RVMDSPY

Wall St. Highest PT $320.00 (+71.8%) Wall St. Avg PT $257.84 (+38.5%)

Underwater Drawdown %Max DD -25.0%Current -15.8%

Relative Strength vs SPY+207.6% vs SPYOutperforming

−$10.33 (5.26%)

−$18.75 (9.15%)

+$2.36 (1.28%)

+$41.39 (28.58%)

YTD

+$106.57 (133.80%)

+$128.23 (221.12%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar

Wall Street analyst consensus

Strong Buy

25 analysts · mean score 1.28

1 = Strong Buy · 5 = Sell

Strong Buy1976%

Buy520%

Hold14%

Underperform00%

Sell00%

Wall Street consensus · as of Oct 22, 2026

Analyst price targets

Current price$186.22

Average target$257.53

+$71.31 (+38.3%) upsideaverage target vs current price

CurrentAverageMedian

Low$179.00

Median$260.00

High$320.00

12-month Wall Street target range · as of Oct 22, 2026

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$42.1B

P/E (next 12 months, estimated)-33.9

52-week range$52.48 – $224.31

Dividend yieldNo dividend

Analyst consensusStrong Buy (24)

Average analyst price target$257.84 (+38%)

What they do

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents.

Healthcare · Biotechnology

Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for RVMD yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Held by 2 of 7 live models: New Highs Growth, SURVYR. Long Book.

New Highs Growth

4.0% of the book · ranked 3 of 589

Held SURVYR. Long Book

2.5% of the book · Higher-risk sleeve

Held Quality Growth

Outside this model's universe or screens

Momentum Top 15

Outside this model's universe or screens

Momentum Blend

Not in the current book

SURVYR. Barbell Momentum & T-Bill Shield

Outside this model's universe or screens

SURVYR. Physical AI Grid & Power

Outside this model's universe or screens

Why it's in the New Highs Growth #3 of 589

Qualified on Biotech, -7% from 52-week high, biotech, price-only entry, 12-1 momentum +346%. Ranked 3rd of 589 at the 2026-09-30 rebalance.

What would knock it out: Drops out if it falls outside the top 25 at the next rebalance (Oct 30). In the latest preview (2026-10-27) it is outside the top 25.

Why it's in the SURVYR. Long Book

Picked for this research portfolio at the Oct 21, 2026 close (Higher-risk group, Biotech & health).

What would knock it out: Weights are fixed and there is no rebalance rule. Any change would be dated and shown here.

Earnings & events

RVMD earningsNext report in 7 days

Next report · quarter Sep 2026

Wed Nov 4, 2026After the close

EPS consensus-$2.38

Revenue consensus–

Last 4 quarters · EPS vs estimate

Aug 5, 2026-$3.06est -$2.06−48.8%Below estimates

May 6, 2026-$2.29est -$1.84−24.6%Below estimates

Feb 25, 2026-$1.86est -$1.56−18.9%Below estimates

Nov 5, 2025-$1.61est -$1.41−14.3%Below estimates

In line = within 1% of the estimate.

EstimateActual (beat)Actual (miss)

News & catalysts

More news

Billionaire Stanley Druckenmiller Added to Revolution Medicines Before Its FDA Win. Is the Stock Still a Buy After a 134% Run?

Nasdaq · 9h ago

Revolution Medicines to Participate in November 2026 Investor Conferences

GlobeNewswire · 10h ago

What 3 multibillion dollar biotechs still have to prove

Pharma Voice · 18h ago

Cantargia Appoints Dr. Monic Stuart as Chief Medical Officer

ACCESS Newswire · Oct 26

Roche Targets Emerging Oncology Market With New Lung-Cancer Drug

The Wall Street Journal · Oct 25